Cialis

http://www.businesswire.com/cnn/icos.shtml

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the Company's results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in the Company's latest Annual Report on Form 10-K and its other public filings filed with the Securities and Exchange Commission.

Lilly Icos applies for European approval of Cialis
Lilly Icos LLC, a joint venture between Icos Corp. of Bothell and Eli Lilly and Co. of Indianapolis, Ind., said Thursday it has filed an application for approval of Cialis, its erectile dysfunction treatment, for use in Europe. The filing, made to the European Agency for the Evaluation of Medicinal Products, follows closely the June 28 new drug application for Cialis to the U.S. Food and Drug Administration for use in the United States.